Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deferoxamine improves left ventricular function in beta-thalassemia.

D Grisaru, A W Goldfarb, M S Gotsman

    Archives of Internal Medicine
    |December 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    What is the right timing for ultrasound evaluation after pregnancy termination with mifepristone?

    European journal of obstetrics, gynecology, and reproductive biology·2015
    Same author

    Correlation of cancer risk evaluation and early detection (CADET) scores with abnormal ultrasonographic ovarian findings.

    European journal of gynaecological oncology·2012
    Same author

    Selective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS.

    Leukemia research·2012
    Same author

    Early adenocarcinoma of the cervix: is radical vaginal trachelectomy safe?

    Gynecologic oncology·2011
    Same author

    2-Butoxyethanol model of haemolysis and disseminated thrombosis in female rats: a preliminary study of the vascular mechanism of osteoarthritis in the temporomandibular joint.

    The British journal of oral & maxillofacial surgery·2009
    Same author

    Evaluating the impact of age and disease on survival of chronic lymphocytic leukaemia patients by a new method.

    International journal of clinical practice·2009
    Same journal

    Elevated CK-MB With Normal Total Creatine Kinase Levels in Patients Undergoing Maintenance Hemodialysis-Reply.

    Archives of internal medicine·2017
    Same journal

    Occult Carbon Monoxide Poisoning-Reply.

    Archives of internal medicine·2017
    Same journal

    Acquired Immune Deficiency Syndrome-Reply.

    Archives of internal medicine·2017
    Same journal

    Heparin Side Effects-Reply.

    Archives of internal medicine·2017
    Same journal

    Humanizing primary care medicine begins with stress.

    Archives of internal medicine·2017
    Same journal

    Legend omitted and number misrepresented.

    Archives of internal medicine·2013
    See all related articles

    Deferoxamine therapy in thalassemia patients improves left ventricular (LV) function and reduces LV wall mass. This treatment, combined with blood transfusions, prevents cardiac deterioration and may reverse existing damage.

    Area of Science:

    • Cardiology
    • Hematology
    • Pharmacology

    Background:

    • Thalassemia patients often develop cardiac complications due to iron overload.
    • Left ventricular (LV) dysfunction and increased LV wall mass are significant concerns.

    Purpose of the Study:

    • To evaluate the effect of deferoxamine therapy on LV function and wall mass in thalassemia patients.
    • To compare outcomes between patients receiving deferoxamine and those not receiving it.

    Main Methods:

    • Serial echocardiographic examinations were performed on 35 thalassemia patients over 5.5 years.
    • Twenty patients received deferoxamine sulfate (drug group), while 15 did not (nondrug group).
    • All patients maintained pretransfusion hemoglobin levels at 9 g/dL via blood transfusions.

    Related Experiment Videos

    Main Results:

    • Deferoxamine therapy significantly improved LV function, evidenced by improved percentage shortening of LV diameter and posterior wall motion velocity.
    • LV wall mass decreased in the drug group compared to the nondrug group.
    • In some patients, deferoxamine reversed existing LV systolic dysfunction.

    Conclusions:

    • Deferoxamine therapy, alongside modest blood transfusions, can prevent cardiac deterioration in thalassemia patients.
    • This treatment may improve LV systolic function and reverse pathological processes increasing LV wall mass.